He RH, He YJ, Tang YJ, Zhou HH, McLeod HL, Liu J (2016) The potential anticancer effect of beta-blockers and the genetic variations involved in the interindividual difference. Pharmacogenomics 17(1):74–79

PubMed  Article  CAS  Google Scholar 

Shahrokhi M, Gupta V (2020) Propranolol. StatPearls, Treasure Island (FL)

Google Scholar 

Oliver E, Mayor F Jr, D’Ocon P (2019) Beta-blockers: historical perspective and mechanisms of action. Rev Esp Cardiol (Engl Ed) 72(10):853–862

Article  Google Scholar 

Hagen R, Ghareeb E, Jalali O, Zinn Z (2018) Infantile hemangiomas: what have we learned from propranolol? Curr Opin Pediatr 30(4):499–504

CAS  PubMed  Article  Google Scholar 

Perron L, Bairati I, Harel F, Meyer F (2004) Antihypertensive drug use and the risk of prostate cancer (Canada). Cancer Causes Control 15(6):535–541

PubMed  Article  Google Scholar 

Powe DG, Voss MJ, Zanker KS, Habashy HO, Green AR, Ellis IO et al (2010) Beta-blocker drug therapy reduces secondary cancer formation in breast cancer and improves cancer specific survival. Oncotarget 1(7):628–638

PubMed  PubMed Central  Article  Google Scholar 

De Giorgi V, Gandini S, Grazzini M, Benemei S, Marchionni N, Geppetti P (2013) Effect of beta-blockers and other antihypertensive drugs on the risk of melanoma recurrence and death. Mayo Clin Proc 88(11):1196–1203

PubMed  Article  CAS  Google Scholar 

Liao P, Song K, Zhu Z, Liu Z, Zhang W, Li W et al (2020) Propranolol suppresses the growth of colorectal cancer through simultaneously activating autologous CD8(+) T cells and inhibiting tumor AKT/MAPK pathway. Clin Pharmacol Ther 108(3):606–615

CAS  PubMed  Article  Google Scholar 

Zhou C, Chen X, Zeng W, Peng C, Huang G, Li X et al (2016) Propranolol induced G0/G1/S phase arrest and apoptosis in melanoma cells via AKT/MAPK pathway. Oncotarget 7(42):68314–68327

PubMed  PubMed Central  Article  Google Scholar 

De Giorgi V, Grazzini M, Benemei S, Marchionni N, Botteri E, Pennacchioli E et al (2018) Propranolol for off-label treatment of patients with melanoma: results from a cohort study. JAMA Oncol 4(2):e172908

PubMed  Article  Google Scholar 

Killock D (2017) Skin cancer: propranolol limits melanoma recurrence. Nat Rev Clin Oncol 14(12):714

PubMed  Article  Google Scholar 

Hiller JG, Cole SW, Crone EM, Byrne DJ, Shackleford DM, Pang JB et al (2020) Preoperative beta-blockade with propranolol reduces biomarkers of metastasis in breast cancer: a phase II randomized trial. Clin Cancer Res 26(8):1803–1811

CAS  PubMed  Article  Google Scholar 

Spini A, Roberto G, Gini R, Bartolini C, Bazzani L, Donnini S et al (2019) Evidence of beta-blockers drug repurposing for the treatment of triple negative breast cancer: a systematic review. Neoplasma 66(6):963–970

CAS  PubMed  Article  Google Scholar 

Ramondetta LM, Hu W, Thaker PH, Urbauer DL, Chisholm GB, Westin SN et al (2019) Prospective pilot trial with combination of propranolol with chemotherapy in patients with epithelial ovarian cancer and evaluation on circulating immune cell gene expression. Gynecol Oncol 154(3):524–530

CAS  PubMed  PubMed Central  Article  Google Scholar 

Yang EV, Kim SJ, Donovan EL, Chen M, Gross AC, Webster Marketon JI et al (2009) Norepinephrine upregulates VEGF, IL-8, and IL-6 expression in human melanoma tumor cell lines: implications for stress-related enhancement of tumor progression. Brain Behav Immun 23(2):267–275

CAS  PubMed  Article  Google Scholar 

Moretti S, Massi D, Farini V, Baroni G, Parri M, Innocenti S et al (2013) Beta-adrenoceptors are upregulated in human melanoma and their activation releases pro-tumorigenic cytokines and metalloproteases in melanoma cell lines. Lab Invest 93(3):279–290

CAS  PubMed  Article  Google Scholar 

Inigo-Marco I, Alonso MM (2019) Destress and do not suppress: targeting adrenergic signaling in tumor immunosuppression. J Clin Invest 129(12):5086–5088

CAS  PubMed  PubMed Central  Article  Google Scholar 

Hu Q, Liao P, Li W, Hu J, Chen C, Zhang Y et al (2021) Clinical use of propranolol reduces biomarkers of proliferation in gastric cancer. Front Oncol 11:628613

PubMed  PubMed Central  Article  Google Scholar 

Montoya A, Varela-Ramirez A, Dickerson E, Pasquier E, Torabi A, Aguilera R et al (2019) The beta adrenergic receptor antagonist propranolol alters mitogenic and apoptotic signaling in late stage breast cancer. Biomed J 42(3):155–165

PubMed  PubMed Central  Article  Google Scholar 

Masur K, Niggemann B, Zanker KS, Entschladen F (2001) Norepinephrine-induced migration of SW 480 colon carcinoma cells is inhibited by beta-blockers. Cancer Res 61(7):2866–2869

CAS  PubMed  Google Scholar 

Sood AK, Bhatty R, Kamat AA, Landen CN, Han L, Thaker PH et al (2006) Stress hormone-mediated invasion of ovarian cancer cells. Clin Cancer Res 12(2):369–375

CAS  PubMed  PubMed Central  Article  Google Scholar 

Guo K, Ma Q, Wang L, Hu H, Li J, Zhang D et al (2009) Norepinephrine-induced invasion by pancreatic cancer cells is inhibited by propranolol. Oncol Rep 22(4):825–830

CAS  PubMed  Google Scholar 

Mohammadpour H, MacDonald CR, Qiao G, Chen M, Dong B, Hylander BL et al (2019) beta2 adrenergic receptor-mediated signaling regulates the immunosuppressive potential of myeloid-derived suppressor cells. J Clin Invest 129(12):5537–5552

CAS  PubMed  PubMed Central  Article  Google Scholar 

Zhang X, Zhang Y, He Z, Yin K, Li B, Zhang L et al (2019) Chronic stress promotes gastric cancer progression and metastasis: an essential role for ADRB2. Cell Death Dis 10(11):788

PubMed  PubMed Central  Article  CAS  Google Scholar 

Bucsek MJ, Qiao G, MacDonald CR, Giridharan T, Evans L, Niedzwecki B et al (2017) Beta-adrenergic signaling in mice housed at standard temperatures suppresses an effector phenotype in CD8(+) T cells and undermines checkpoint inhibitor therapy. Cancer Res 77(20):5639–5651

CAS  PubMed  PubMed Central  Article  Google Scholar 

Qiao G, Bucsek MJ, Winder NM, Chen M, Giridharan T, Olejniczak SH et al (2019) beta-Adrenergic signaling blocks murine CD8(+) T-cell metabolic reprogramming during activation: a mechanism for immunosuppression by adrenergic stress. Cancer Immunol Immunother 68(1):11–22

CAS  PubMed  Article  Google Scholar 

Estrada LD, Agac D, Farrar JD (2016) Sympathetic neural signaling via the beta2-adrenergic receptor suppresses T-cell receptor-mediated human and mouse CD8(+) T-cell effector function. Eur J Immunol 46(8):1948–1958

CAS  PubMed  PubMed Central  Article  Google Scholar 

Yeo W, Chan SL, Mo FK, Chu CM, Hui JW, Tong JH et al (2015) Phase I/II study of temsirolimus for patients with unresectable Hepatocellular Carcinoma (HCC)- a correlative study to explore potential biomarkers for response. BMC Cancer 15:395

PubMed  PubMed Central  Article  CAS  Google Scholar 

Budwit-Novotny DA, McCarty KS, Cox EB, Soper JT, Mutch DG, Creasman WT et al (1986) Immunohistochemical analyses of estrogen receptor in endometrial adenocarcinoma using a monoclonal antibody. Cancer Res 46(10):5419–5425

CAS  PubMed  Google Scholar 

Mutch DG, Soper JT, Budwit-Novotny DA, Cox EB, Creasman WT, McCarty KS Sr et al (1987) Endometrial adenocarcinoma estrogen receptor content: association of clinicopathologic features with immunohistochemical analysis compared with standard biochemical methods. Am J Obstet Gynecol 157(4 Pt 1):924–931

CAS  PubMed  Article  Google Scholar 

Chin CC, Li JM, Lee KF, Huang YC, Wang KC, Lai HC et al (2016) Selective beta2-AR blockage suppresses colorectal cancer growth through regulation of EGFR-Akt/ERK1/2 signaling, G1-phase arrest, and apoptosis. J Cell Physiol 231(2):459–472

CAS  PubMed  Article  Google Scholar 

Wong HP, Yu L, Lam EK, Tai EK, Wu WK, Cho CH (2007) Nicotine promotes colon tumor growth and angiogenesis through beta-adrenergic activation. Toxicol Sci 97(2):279–287

CAS  PubMed  Article  Google Scholar 

Zhang D, Ma Q, Wang Z, Zhang M, Guo K, Wang F et al (2011) Beta2-adrenoceptor blockage induces G1/S phase arrest and apoptosis in pancreatic cancer cells via Ras/Akt/NFkappaB pathway. Mol Cancer 10:146

CAS  PubMed  PubMed Central  Article  Google Scholar 

Burotto M, Chiou VL, Lee JM, Kohn EC (2014) The MAPK pathway across different malignancies: a new perspective. Cancer 120(22):3446–3456

CAS  PubMed  Article  Google Scholar 

Munabi NC, England RW, Edwards AK, Kitajewski AA, Tan QK, Weinstein A et al (2016) Propranolol targets hemangioma stem cells via cAMP and mitogen-activated protein kinase regulation. Stem Cells Transl Med 5(1):45–55

CAS  PubMed  Article  Google Scholar 

Zou HX, Jia J, Zhang WF, Sun ZJ, Zhao YF (2013) Propranolol inhibits endothelial progenitor cell homing: a possible treatment mechanism of infantile hemangioma. Cardiovasc Pathol 22(3):203–210

CAS  PubMed  Article  Google Scholar 

Xie WY, He RH, Zhang J, He YJ, Wan Z, Zhou CF et al (2019) betablockers inhibit the viability of breast cancer cells by regulating the ERK/COX2 signaling pathway and the drug response is affected by ADRB2 singlenucleotide polymorphisms. Oncol Rep 41(1):341–350

CAS  PubMed  Google Scholar